Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy

D. J. Macey, S. J. DeNardo, Gerald L Denardo, D. A. DeNardo, S. Shen

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Myelotoxicity is the dose-limiting factor in radioimmunotherapy. Traditional methods most commonly used to estimate the radiation adsorbed dose to the bone marrow of patients consider contributions from radionuclide in the blood and/or total body. Targeted therapies, such as radioimmunotherapy, add a third potential source for radiation to the bone marrow because the radiolabeled targeting molecules can accumulate specifically on malignant target cells infiltrating the bone marrow. A noninvasive method for estimating the radiation absorbed dose to the red marrow of patients who have received radiolabeled monoclonal antibodies (MoAb) has been developed and explored. The method depends on determining the cumulated activity in three contributing sources: 1) marrow; 2) blood; and 3) total body. The novel aspect of this method for estimating marrow radiation dose is derivation of the radiation dose for the entire red marrow from radiation dose estimates obtained by detection of cumulated activity In three lumbar vertebrae using a gamma camera. Contributions to the marrow radiation dose from marrow, blood, and total body cumulated activity were determined for patients who received an I-131 labeled MoAb, Lym-1, that reacts with malignant B-lymphocytes of chronic lymphocytic leukemia and nonHodgkin's lymphoma. Six patients were selected for Illustrative purposes because their vertebrae were readily visualized on lumbar images. The radiation doses to the marrow contributed by nonpenetrating emissions in the marrow blood and penetrating emissions in the total body were similar in these patients with a mean of 0.2 and 0.3 rads per administered mCl from the blood and total body, respectively. However, the radiation doses to the marrow from nonpenetrating emissions of I-131 that targeted marrow malignancy varied greatly and ranged from 0.6-2.9 rads per administered mCl in these selected patients. The latter source of marrow radiation dose was often greater than the combined contribution of the blood and total body to marrow radiation dose; this source of marrow radiation dose is ignored by traditional approaches to bone marrow dosimetry and is important to consider for targeted therapies such as radioimmunotherapy. Although it is not appropriate to suggest that the marrow radiation doses estimated using the novel imaging method described are accurate, their use did predict greater hematologic toxicity in the 6 patients and this toxicity was not anticipated from the marrow radiation doses estimated by using the traditional blood and total body contributions. The exact role of the imaging method remains to be determined and additional validation is required. Although further comparisons with data for hematologic toxicities and results from bone marrow biopsies are required, the method has the potential for providing the therapist with a predictor of greater likelihood of myelotoxicity. Imaging studies with the intended therapeutic agent can be obtained for an individual patient so that predictions can be made before the implementation of therapy.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalClinical Nuclear Medicine
Volume20
Issue number2
DOIs
StatePublished - 1995

Fingerprint

Radioimmunotherapy
Bone Marrow
Radiation
B-Cell Chronic Lymphocytic Leukemia

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. / Macey, D. J.; DeNardo, S. J.; Denardo, Gerald L; DeNardo, D. A.; Shen, S.

In: Clinical Nuclear Medicine, Vol. 20, No. 2, 1995, p. 117-125.

Research output: Contribution to journalArticle

Macey, D. J. ; DeNardo, S. J. ; Denardo, Gerald L ; DeNardo, D. A. ; Shen, S. / Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. In: Clinical Nuclear Medicine. 1995 ; Vol. 20, No. 2. pp. 117-125.
@article{862be9b8220845c2bfa285d20a56c3a8,
title = "Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy",
abstract = "Myelotoxicity is the dose-limiting factor in radioimmunotherapy. Traditional methods most commonly used to estimate the radiation adsorbed dose to the bone marrow of patients consider contributions from radionuclide in the blood and/or total body. Targeted therapies, such as radioimmunotherapy, add a third potential source for radiation to the bone marrow because the radiolabeled targeting molecules can accumulate specifically on malignant target cells infiltrating the bone marrow. A noninvasive method for estimating the radiation absorbed dose to the red marrow of patients who have received radiolabeled monoclonal antibodies (MoAb) has been developed and explored. The method depends on determining the cumulated activity in three contributing sources: 1) marrow; 2) blood; and 3) total body. The novel aspect of this method for estimating marrow radiation dose is derivation of the radiation dose for the entire red marrow from radiation dose estimates obtained by detection of cumulated activity In three lumbar vertebrae using a gamma camera. Contributions to the marrow radiation dose from marrow, blood, and total body cumulated activity were determined for patients who received an I-131 labeled MoAb, Lym-1, that reacts with malignant B-lymphocytes of chronic lymphocytic leukemia and nonHodgkin's lymphoma. Six patients were selected for Illustrative purposes because their vertebrae were readily visualized on lumbar images. The radiation doses to the marrow contributed by nonpenetrating emissions in the marrow blood and penetrating emissions in the total body were similar in these patients with a mean of 0.2 and 0.3 rads per administered mCl from the blood and total body, respectively. However, the radiation doses to the marrow from nonpenetrating emissions of I-131 that targeted marrow malignancy varied greatly and ranged from 0.6-2.9 rads per administered mCl in these selected patients. The latter source of marrow radiation dose was often greater than the combined contribution of the blood and total body to marrow radiation dose; this source of marrow radiation dose is ignored by traditional approaches to bone marrow dosimetry and is important to consider for targeted therapies such as radioimmunotherapy. Although it is not appropriate to suggest that the marrow radiation doses estimated using the novel imaging method described are accurate, their use did predict greater hematologic toxicity in the 6 patients and this toxicity was not anticipated from the marrow radiation doses estimated by using the traditional blood and total body contributions. The exact role of the imaging method remains to be determined and additional validation is required. Although further comparisons with data for hematologic toxicities and results from bone marrow biopsies are required, the method has the potential for providing the therapist with a predictor of greater likelihood of myelotoxicity. Imaging studies with the intended therapeutic agent can be obtained for an individual patient so that predictions can be made before the implementation of therapy.",
author = "Macey, {D. J.} and DeNardo, {S. J.} and Denardo, {Gerald L} and DeNardo, {D. A.} and S. Shen",
year = "1995",
doi = "10.1097/00003072-199502000-00005",
language = "English (US)",
volume = "20",
pages = "117--125",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy

AU - Macey, D. J.

AU - DeNardo, S. J.

AU - Denardo, Gerald L

AU - DeNardo, D. A.

AU - Shen, S.

PY - 1995

Y1 - 1995

N2 - Myelotoxicity is the dose-limiting factor in radioimmunotherapy. Traditional methods most commonly used to estimate the radiation adsorbed dose to the bone marrow of patients consider contributions from radionuclide in the blood and/or total body. Targeted therapies, such as radioimmunotherapy, add a third potential source for radiation to the bone marrow because the radiolabeled targeting molecules can accumulate specifically on malignant target cells infiltrating the bone marrow. A noninvasive method for estimating the radiation absorbed dose to the red marrow of patients who have received radiolabeled monoclonal antibodies (MoAb) has been developed and explored. The method depends on determining the cumulated activity in three contributing sources: 1) marrow; 2) blood; and 3) total body. The novel aspect of this method for estimating marrow radiation dose is derivation of the radiation dose for the entire red marrow from radiation dose estimates obtained by detection of cumulated activity In three lumbar vertebrae using a gamma camera. Contributions to the marrow radiation dose from marrow, blood, and total body cumulated activity were determined for patients who received an I-131 labeled MoAb, Lym-1, that reacts with malignant B-lymphocytes of chronic lymphocytic leukemia and nonHodgkin's lymphoma. Six patients were selected for Illustrative purposes because their vertebrae were readily visualized on lumbar images. The radiation doses to the marrow contributed by nonpenetrating emissions in the marrow blood and penetrating emissions in the total body were similar in these patients with a mean of 0.2 and 0.3 rads per administered mCl from the blood and total body, respectively. However, the radiation doses to the marrow from nonpenetrating emissions of I-131 that targeted marrow malignancy varied greatly and ranged from 0.6-2.9 rads per administered mCl in these selected patients. The latter source of marrow radiation dose was often greater than the combined contribution of the blood and total body to marrow radiation dose; this source of marrow radiation dose is ignored by traditional approaches to bone marrow dosimetry and is important to consider for targeted therapies such as radioimmunotherapy. Although it is not appropriate to suggest that the marrow radiation doses estimated using the novel imaging method described are accurate, their use did predict greater hematologic toxicity in the 6 patients and this toxicity was not anticipated from the marrow radiation doses estimated by using the traditional blood and total body contributions. The exact role of the imaging method remains to be determined and additional validation is required. Although further comparisons with data for hematologic toxicities and results from bone marrow biopsies are required, the method has the potential for providing the therapist with a predictor of greater likelihood of myelotoxicity. Imaging studies with the intended therapeutic agent can be obtained for an individual patient so that predictions can be made before the implementation of therapy.

AB - Myelotoxicity is the dose-limiting factor in radioimmunotherapy. Traditional methods most commonly used to estimate the radiation adsorbed dose to the bone marrow of patients consider contributions from radionuclide in the blood and/or total body. Targeted therapies, such as radioimmunotherapy, add a third potential source for radiation to the bone marrow because the radiolabeled targeting molecules can accumulate specifically on malignant target cells infiltrating the bone marrow. A noninvasive method for estimating the radiation absorbed dose to the red marrow of patients who have received radiolabeled monoclonal antibodies (MoAb) has been developed and explored. The method depends on determining the cumulated activity in three contributing sources: 1) marrow; 2) blood; and 3) total body. The novel aspect of this method for estimating marrow radiation dose is derivation of the radiation dose for the entire red marrow from radiation dose estimates obtained by detection of cumulated activity In three lumbar vertebrae using a gamma camera. Contributions to the marrow radiation dose from marrow, blood, and total body cumulated activity were determined for patients who received an I-131 labeled MoAb, Lym-1, that reacts with malignant B-lymphocytes of chronic lymphocytic leukemia and nonHodgkin's lymphoma. Six patients were selected for Illustrative purposes because their vertebrae were readily visualized on lumbar images. The radiation doses to the marrow contributed by nonpenetrating emissions in the marrow blood and penetrating emissions in the total body were similar in these patients with a mean of 0.2 and 0.3 rads per administered mCl from the blood and total body, respectively. However, the radiation doses to the marrow from nonpenetrating emissions of I-131 that targeted marrow malignancy varied greatly and ranged from 0.6-2.9 rads per administered mCl in these selected patients. The latter source of marrow radiation dose was often greater than the combined contribution of the blood and total body to marrow radiation dose; this source of marrow radiation dose is ignored by traditional approaches to bone marrow dosimetry and is important to consider for targeted therapies such as radioimmunotherapy. Although it is not appropriate to suggest that the marrow radiation doses estimated using the novel imaging method described are accurate, their use did predict greater hematologic toxicity in the 6 patients and this toxicity was not anticipated from the marrow radiation doses estimated by using the traditional blood and total body contributions. The exact role of the imaging method remains to be determined and additional validation is required. Although further comparisons with data for hematologic toxicities and results from bone marrow biopsies are required, the method has the potential for providing the therapist with a predictor of greater likelihood of myelotoxicity. Imaging studies with the intended therapeutic agent can be obtained for an individual patient so that predictions can be made before the implementation of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028801673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028801673&partnerID=8YFLogxK

U2 - 10.1097/00003072-199502000-00005

DO - 10.1097/00003072-199502000-00005

M3 - Article

C2 - 7720301

AN - SCOPUS:0028801673

VL - 20

SP - 117

EP - 125

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 2

ER -